• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Bausch + Lomb makes another eye drop acquisition

July 6, 2023 By Sean Whooley

Bausch + Lomb (1)Bausch + Lomb (NYSE:BLCO) announced today that an affiliate purchased the Blink product line from Johnson & Johnson Vision.

The over-the-counter Blink product line features eye and contact lens drops, marking another eye care acquisition for Bausch + Lomb. Last week, the company acquired eye drops and a delivery system from Novartis in a deal worth up to $2.5 billion.

Under the terms of this deal, Bausch + Lomb plans to use cash on hand to acquire the Blink line for $106.5 million.

“There’s a growing need for relieving the symptoms of dry eyes and dry contact lenses, and OTC products are often the first option consumers choose,” said John Ferris, EVP, Consumer, Bausch + Lomb. “The addition of Blink expands our robust portfolio of OTC eye care brands, enabling us to provide more choices for consumers and eye care professionals.”

Blink features a variety of eye drops and contact lens resetting drops. They provide immediate and long-lasting symptom relief.

Products involved in the acquisition include:

  • Blink Tears Lubricating Eye Drops;
  • Blink Tears Preservative Free Lubricating Eye Drops;
  • Blink GelTears Lubricating Eye Drops;
  • Blink Triple Care Lubricating Eye Drops;
  • Blink Contacts Lubricating Eye Drops; and
  • Blink-N-Clean Lens Drops.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Mergers & Acquisitions, Optical/Ophthalmic Tagged With: bausch&lomb, Johnson & Johnson Vision

IN CASE YOU MISSED IT

  • Dexcom Q3 earnings top forecasts, as it looks ahead to type 2 coverage
  • Sensonics launches human feasibility study for transmitter-free Eversense CGM
  • Enable Injections, Sanofi obtain approval for on-body myeloma therapy in Japan
  • Abbott sets Libre Duo glucose-ketone sensor US launch for December
  • Sequel Med Tech’s automated twiist pump scores FDA clearance in type 2 diabetes

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS